5,000 volunteers tracked to see if chikungunya vaccine is safe
NCT ID NCT07254702
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This observational study will follow 5,000 people who received the VLA1553 chikungunya vaccine as part of a pilot vaccination program. Researchers will monitor for specific safety concerns like chikungunya-like reactions, heart problems, and arthritis over 60 days. The goal is to estimate how often these side effects occur and measure any increased risk linked to the vaccine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VLA1553 live-attenuated chikungunya vaccine
What this could lead to
If this study confirms the vaccine is safe, it could support wider use of VLA1553 to prevent chikungunya virus infection.
What could go wrong
This is an observational study, not a controlled trial, so it can't prove cause and effect. Rare side effects may still be missed even with 5,000 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus
Laranjeiras, Sergipe, 49060-025, Brazil
-
Fundação Faculdade Regional De Medicina De São José Do Rio Preto
São Pedro, São Paulo, 15090-000, Brazil
-
Universidade Federal Do Ceará
Fortaleza, Ceará, 60430-160, Brazil
-
Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras
Belo Horizonte, Minas Gerais, 31270-901, Brazil